Abstracts Archive - Page 124 of 2607 - ACR Meeting Abstracts

Abstract Number: 1679 • ACR Convergence 2025
Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
Cécile VAN MULLEM¹, Francesco NATALUCCI¹, Stéphanie DIERCKX¹, Aleksandra AVRAMOVSKA¹, Tatiana SOKOLOVA² and Patrick Durez¹, ¹Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Background/Purpose: The management of Rheumatoid Arthritis (RA) has markedly advanced, enabling the achievement of disease control and remission. Nevertheless, a proportion of patients remains refractory…
Abstract Number: 1698 • ACR Convergence 2025
X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
Desire Casares Marfil¹, Gülşah Kavrul Kayaalp², Vafa Guliyeva², Özlem Akgün², Şeyma Türkmen³, Elif Kilic Konte⁴, Sezgin Sahin⁴, Ozgur Kasapcopur⁵, Betul Sozeri⁶, Selçuk Sözer Tokdemir⁷, Nuray Aktay Ayaz⁸ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Istanbul University Faculty of Medicine, Istanbul, Turkey, ³University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁶Health sciences university, Istanbul, Turkey, ⁷Istanbul University, Istanbul, Turkey, ⁸Istanbul University Medical School, Istanbul, Turkey
Background/Purpose: DNA methylation plays a critical role in the pathogenesis of lupus. Although most epigenetic studies have focused on autosomal regions, the X chromosome remains…
Abstract Number: 1714 • ACR Convergence 2025
The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis
Lihi Eder¹, Xianwei Li², Sahil Koppikar³, Iliana Lega⁴, Dafna D. Gladman⁵, Vinod Chandran¹ and Richard Cook⁶, ¹University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, ³Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁴University of Toronto and Women’s College Hospital, Toronto, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada
Background/Purpose: Perimenopause is associated with a wide spectrum of symptoms, including mood changes, sleep disturbances, and joint pains. Limited information exists on the effect of…
Abstract Number: 1747 • ACR Convergence 2025
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Mark Chaballa⁶, Vadim Khaychuk⁷, Misti Paudel⁸ and Jeffrey Sparks⁹, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Pennington, NJ, ⁸Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), contributes significantly to morbidity and mortality in RA patients. RA…
Abstract Number: 1626 • ACR Convergence 2025
A Delphi Exercise Informing the Development of Criteria to Measure Response to Treatment in Giant Cell Arteritis
Medha Soowamber¹, Milena Bond², Catalina Sanchez Alvarez³, Carol Langford⁴, Sibel Aydin⁵, FRANK BUTTGEREIT⁶, Dario Camellino⁷, Maria Cid⁸, Peter Grayson⁹, Bernhard Hellmich¹⁰, Tanaz Kermani¹¹, Nader Khalidi¹², Sarah Mackie¹³, Alfred Mahr¹⁴, Eric L Matteson³, Mehrdad Maz¹⁵, Peter Merkel¹⁶, Paul Monach¹⁷, Lorna Neill¹⁸, Cristina Ponte¹⁹, Carlo Salvarani²⁰, Wolfgang Schmidt²¹, Peter Villiger²², Kenneth Warrington²³, Christian Dejaco²⁴, Sofia Ramiro²⁵ and Zahi Touma²⁶, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, ³Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Cleveland Clinic, Moreland Hills, OH, ⁵Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany, ⁷"La Colletta" hospital, Azienda Sanitaria Locale ³ Genovese, Arenzano, Italy, ⁸Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁰Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ¹¹David Geffen School of Medicine, University of California, Los Angeles, CA, ¹²Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ¹³University of Leeds, Leeds, United Kingdom, ¹⁴Klinik für Rheumatologie, Kantonspital St Gallen, St Gallen, Switzerland, ¹⁵The University of Kansas Medical Center, Kansas City, KS, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷VA Boston Healthcare System, Boston, MA, ¹⁸Patient Charity Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Nethy Bridge, United Kingdom, ¹⁹Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, ²⁰Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²¹Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ²²Medical Center Monbijou, Rheumatology and Clinical Immunology, Bern, Switzerland, ²³Mayo Clinic, ROCHESTER, MN, ²⁴Medical University of Graz, Graz, Austria, ²⁵Leiden University Medical Center, Bunde, Netherlands, ²⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: The therapeutic landscape of giant cell arteritis (GCA) is growing rapidly but there are currently no internationally standardized criteria for assessing response to treatment…
Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 1713 • ACR Convergence 2025
Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients
Mohamed Abdelsalam¹, Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Abdelhfeez Moshrif⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Al Azhar University, Asyut, Egypt, assyut, Asyut, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Psoriatic arthritis (PsA) remains widely underdiagnosed and misdiagnosed worldwide, leading to delays in appropriate management and increased disease burden. While diagnostic delay has been…
Abstract Number: 1720 • ACR Convergence 2025
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Khadija Mohib¹, Rameez Qasim², Zaiya Waseem³, Shaheer Ahmad⁴ and Ahmad Ali Hussain⁵, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³AtlantiCare Regional Medical Center, New Jersey, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Allama Iqbal Medical College Lahore, Lahore
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) are chronic autoimmune diseases with significant morbidity and mortality, collectively accounting for approximately 5,000 deaths…
Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 1722 • ACR Convergence 2025
Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
Shivani Garg¹, Benoit Blanchet², Yann Nguyen³, Fauzia Hollnagel⁴, Ada Clarke⁵, Michelle Petri⁶, Murray Urowitz⁷, John Hanly⁸, Caroline Gordon⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Jorge Sanchez-Guerrero¹², Ann Clarke¹³, Sasha Bernatsky¹⁴, Daniel Wallace¹⁵, David A. Isenberg¹⁶, Anisur Rahman¹⁶, Joan Merrill¹⁷, Paul Fortin¹⁸, Dafna D. Gladman¹⁹, Ian Bruce²⁰, Ellen Ginzler²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Susan Manzi²⁴, Andreas Jönsen²⁵, Graciela Alarcón²⁶, Ronald van Vollenhoven²⁷, Cynthia Aranow²⁸, Murat Inanc²⁹, Meghan mackay³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Murat Inac³³, Kenneth Kalunian³⁴, Søren Jacobsen³⁵, Christine Peschken¹¹, Diane Kamen³⁶, Anca Askanase³⁷, Jill Buyon³⁸, Julie Chezel⁵, Alicja Puszkiel³⁹ and Nathalie Costedoat-Chalumeau⁴⁰, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, ³Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ⁴University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ⁵Cochin Hospital, Paris, France, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Toronto, Toronto, ON, Canada, ⁸Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁹Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ¹⁰Hanyang University Medical Center, Seoul, South Korea, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Mount Sinai Hospital and University Health Network, Toronto, Canada, ¹³Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁵Cedars Sinai Medical Center, Studio City, CA, ¹⁶University College London, London, United Kingdom, ¹⁷Oklahoma Medical Research Foundation, Oklahoma, ¹⁸Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ²⁰Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ²¹SUNY Downstate Health Sciences University, New York, NY, ²²UNC physician network, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁵Department of Clinical Sciences, Lund University, Lund, Sweden, ²⁶The University of Alabama at Birmingham, Oakland, CA, ²⁷Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁸Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁹Istanbul University, Istanbul, Turkey, ³⁰Feinstein Institutes for Medical Research, Manhasset, NY, ³¹Biobizkaia Health Research Institute, Barakaldo, Spain, ³²Emory University School of Medicine, Atlanta, GA, ³³Istanbul University, Istanbul, ³⁴UC San Diego, La Jolla, CA, ³⁵Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁶Medical University of South Carolina, Johns Island, SC, ³⁷Columbia University Medical Center, New York, NY, ³⁸NYU Grossman School of Medicine, New York, NY, ³⁹Cochin Hospital, Paris, ⁴⁰Inserm DR Paris ⁵, Paris, France
Background/Purpose: Current guidelines recommend using hydroxychloroquine (HCQ) dose ≤5.0 mg/kg for managing SLE. However, 6-fold higher SLE flares, including those requiring hospitalizations, are noted with…
Abstract Number: 1703 • ACR Convergence 2025
Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging
Wittaya Suwakulsiri¹, Lukas Andriessen², Coline Fournier³, Saritha Kodikara⁴, Amy Anderson⁵, Jasmine Sim⁵, Kim-Anh Le Cao⁴, Yann Abraham⁶, Kevin Wei⁷, Kenneth Baker⁵, Arthur Pratt⁸, Mihir Wechalekar⁹, John Isaacs¹⁰ and Ranjeny Thomas¹, ¹Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ³Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia, ⁴Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia, ⁵Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶DeepLife, Vernon, France, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹Flinders Medical Centre, Adelaide, Australia, ¹⁰Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Many patients living with rheumatoid arthritis (RA) can achieve remission with modern treat-to-target disease-modifying anti-rheumatic drugs (DMARDs), albeit with the risks associated with long-term…
Abstract Number: 1728 • ACR Convergence 2025
Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Jiana Chen¹, Jiaqi Xu¹, Ziyue Zhou², Xu Jiang¹ and Huaxia Yang¹, ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ¹⁰⁰⁷³⁰, Beijing, China, Beijing, China (People's Republic), ²peiking meidical, beijing
Background/Purpose: Immune checkpoint inhibitors (ICIs), while revolutionary in cancer treatment, may induce severe or even fatal immune-related adverse event (irAE). The mechanisms underlying irAE development…
Abstract Number: 1667 • ACR Convergence 2025
Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Zachary Daniel¹, Summia Afridi¹, Michael Allen² and Khoa Ngo¹, ¹Albany Medical College, Albany, NY, ²Albany Med, Albany, NY
Background/Purpose: Up to 30% of patients with incident pericarditis will develop recurrent pericarditis (RP), with severe impact on quality of life. More than 20% of…
Abstract Number: 1742 • ACR Convergence 2025
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Ganesh Ramanathan¹, Justine Ledochowski², Oscar Mwizerwa³, Tala El Tal⁴, Lawrence Ng⁵, Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁷, Joan Wither⁸, Busisiwe Zapparoli⁹, Ashley Danguecan¹⁰ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹The Hospital for Sick Children, Etobicoke, ON, Canada, ¹⁰Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive impairment is common in childhood-onset systemic lupus erythematosus (cSLE), particularly in domains like executive function and attention. However, attributing cognitive difficulties to brain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].